^
    24h
    Pembrolizumab in Treating Patients With Malignant Mesothelioma (clinicaltrials.gov)
    P2, N=65, Completed, University of Chicago | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab)
    1d
    Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Fred Hutchinson Cancer Center
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
    1d
    Detection of DDIT3 gene rearrangement in myxoid liposarcoma using fluorescence in situ hybridization: its clinical application and cryptic signals (PubMed, Zhonghua Bing Li Xue Za Zhi)
    FISH detection of DDIT3 gene rearrangements is important for the diagnosis of MLPS, whereas a small number of cases may still be missed due to cryptic rearrangement. The CR-MLPS cases present typical morphology, among which the EWSR1::DDIT3 variants are more commonly detected than the others.
    Journal
    |
    CDK4 (Cyclin-dependent kinase 4) • EWSR1 (EWS RNA Binding Protein 1) • FUS (FUS RNA Binding Protein) • TP63 (Tumor protein 63) • DDIT3 (DNA-damage-inducible transcript 3)
    1d
    Mesenchymal tumors with GLI1 gene alterations: a clinicopathological analysis of five cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
    While immunophenotyping lacks specificity, and GLI1 immunohistochemistry could aid in its diagnosis. Definitive diagnosis and differential diagnosis of this tumor require characteristic morphological features combined with molecular confirmation of GLI1 gene fusion or amplification.
    Journal
    |
    PTCH1 (Patched 1) • GLI1 (GLI Family Zinc Finger 1) • NCAM1 (Neural cell adhesion molecule 1)
    1d
    Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies. (PubMed, J Immunother Cancer)
    The anti-NKG2A antibody S095029 in combination with anti-PD-1 Sym021 demonstrated a favorable safety profile and exhibited signal of antitumor activity in unselected, heavily pretreated patients with advanced malignancies.
    Clinical • P1 data • Journal • PD(L)-1 Biomarker • IO biomarker • First-in-human
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • HLA-E (Major Histocompatibility Complex, Class I, E) • KLRC1 (Killer Cell Lectin Like Receptor C1) • KLRD1 (Killer Cell Lectin Like Receptor D1)
    |
    S95029 • Sym021
    1d
    Primary Kaposiform hemangioendothelioma of the tibia: report of a case with a previously undescribed GNAQ mutation. (PubMed, Skeletal Radiol)
    Using digital droplet PCR, we identified a previously unreported GNAQ T96S mutation, whereas other GNAQ mutations were not detected. Despite its rarity, recognition of intraosseous KHE is crucial because it allows for prompt curative surgical treatment and avoids potential complications.
    Journal
    |
    GNAQ (G Protein Subunit Alpha Q) • CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    1d
    Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma (clinicaltrials.gov)
    P2, N=3300, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    2d
    Primary Renal Sclerosing Epithelioid Fibrosarcoma With EWSR1::CREB3L1 Fusion: A Diagnostic Pitfall With a Comprehensive Review of Reported Patients. (PubMed, Int J Surg Pathol)
    Notably, within the genitourinary tract, available data suggest a relative predilection for renal involvement. This tumor confirms the broad anatomic spectrum of SEF and underscores the essential role of MUC4 immunohistochemistry and molecular testing in the evaluation of renal tumors with epithelioid cytology and prominent stromal sclerosis.
    Journal
    |
    EWSR1 (EWS RNA Binding Protein 1) • MUC4 (Mucin 4, Cell Surface Associated) • CREB3L1 (CAMP Responsive Element Binding Protein 3 Like 1)
    2d
    Case Report: A giant dedifferentiated liposarcoma in the retroperitoneum. (PubMed, Front Oncol)
    Postoperative pathology combined with fluorescence in situ hybridization (FISH) testing demonstrated MDM2/CDK4 amplification, confirming dedifferentiated liposarcoma (DDLPS). The patient recovered well postoperatively and was discharged following adjuvant radiotherapy (IMRT; 50 Gy in 25 fractions), chemotherapy (AD regimen), and immunotherapy (sintilimab).Through this case, we mainly understand the characteristics of the disease onset, special diagnosis, and main treatment methods.
    Journal
    |
    MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4)
    |
    Tyvyt (sintilimab)